Ignite Creation Date:
2025-12-25 @ 2:34 AM
Ignite Modification Date:
2026-01-05 @ 3:27 PM
Study NCT ID:
NCT02992834
Status:
UNKNOWN
Last Update Posted:
2016-12-14
First Post:
2016-12-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016393', 'term': 'Lymphoma, B-Cell'}], 'ancestors': [{'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'}, {'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 10}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2016-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-12', 'completionDateStruct': {'date': '2022-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2016-12-12', 'studyFirstSubmitDate': '2016-12-12', 'studyFirstSubmitQcDate': '2016-12-12', 'lastUpdatePostDateStruct': {'date': '2016-12-14', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2016-12-14', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2020-08', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'overall survival', 'timeFrame': '5 year'}], 'secondaryOutcomes': [{'measure': 'progression-free survival', 'timeFrame': '56 day'}, {'measure': 'Objective Response Rate', 'timeFrame': '56 day'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'conditions': ['Lymphoma, B Cell']}, 'referencesModule': {'references': [{'pmid': '27924074', 'type': 'BACKGROUND', 'citation': 'Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, Scheinberg DA, Brentjens RJ. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia. 2017 Aug;31(8):1788-1797. doi: 10.1038/leu.2016.373. Epub 2016 Dec 7.'}, {'pmid': '27907031', 'type': 'BACKGROUND', 'citation': 'Minagawa K, Jamil MO, Al-Obaidi M, Pereboeva L, Salzman D, Erba HP, Lamb LS, Bhatia R, Mineishi S, Di Stasi A. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. PLoS One. 2016 Dec 1;11(12):e0166891. doi: 10.1371/journal.pone.0166891. eCollection 2016.'}]}, 'descriptionModule': {'briefSummary': 'This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected allogeneic T-cells in patients with chemotherapy-resistant or refractory CD19+ B cell lymphoma.', 'detailedDescription': 'This is a single-centre, randomised, open label Phase I clinical trial of CD19 Chimeric Antigen Receptor (CAR) T-cells (CD19 CAR T-cells) in patients with chemotherapy-resistant or refractory CD19+ B cell lymphoma. Following informed consent and registration to the trial, Patients will receive the allogeneic CD19 CAR T-cells following lymphodepleting chemotherapy. The study will evaluate the safety, efficacy and duration of response of the CD19 CAR T-cells in patients with chemotherapy-resistant or refractory CD19+ B cell lymphoma.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nEnrollment for enough male or female patients with CD19+ hematological malignancies, without regimens for cure (autologous or allogeneic stem cell transplantation), and having a poor prognosis (several months to 2 years) under current optional regimens\n\n1. Age ranges from 18 to 70 years old\n2. Expected survival time longer than 12 weeks\n3. Performance status score 0-2\n4. Pathologically confirmed CD19+ lymphoma (CD19+ follicular lymphoma, Mantle cell lymphoma, diffuse large B cell lymphoma) and meets at least one of follows:\n\n 1. having received at least 2-4 cycles of combined chemotherapy (excluding monoclonal antibody monotherapy, such as rituximab) but do not reach a complete response; recurrent disease; not applicable for conventional stem cell transplantation; being partial responsible or stable but not complete responsible after the latest therapy\n 2. recurrence develops after stem cell transplantation\n 3. diagnosis confirmed but refusing to receive conventional therapy\n5. Creatinine\\<2.5 mg/dl；\n6. alanine aminotransferase/aspartate aminotransferase lower than 3 folds of normal range\n7. Bilirubin\\<2.0 mg/dl；\n8. Venous channel available and no contraindications for leukocyte collection\n9. Reliable contraception from the beginning to 30 days after discontinuation of therapy\n10. Informed consent signed\n\nExclusion Criteria:\n\n1. Central nerve system invasion with symptoms\n2. Other concurrent uncontrolled malignancies\n3. Hepatitis B infection or active period of hepatitis C, HIV infection\n4. Other uncontrolled diseases hampering the intervention in the study\n5. Coronary heart disease, angina, myocardial infarction, arrhythmia, cerebral thrombosis, cerebral hemorrhage and other serious cardiovascular or cerebrovascular diseases.\n6. Grade 2-3 or uncontrolled hypertension\n7. History of uncontrolled mental disease\n8. Not suitable for participation judged by researchers\n9. Immunosuppressive agents administered due to organ transplantation, not including recent or current inhaled corticosteroid\n10. Medical history of mental diseases or abnormities of lab tests might increase the risks of participation in study or drug administration, or interfering the results\n11. Screening suggesting transfection efficiency of targeting cells lower than 30% or cell expansion deficiency under CD3/CD28 (cluster of differentiation 3,CD3)stimulation (less than 5 folds)\n12. Unstable pulmonary embolism, deep venous thromboembolism or other major arterial/venous thromboembolism events develop in 30 days before the randomization. If anti-coagulation therapy is received, the treatment dose should reach stability before the randomization.\n13. Pregnancy or lactation, or pregnancy planned during the study or in 2 months after the study\n14. Reliable contraception not accepted during the study or in 2 months after the study. Female subjects are required to provide negative results from serum or urine pregnancy test 48 hours before therapy\n15. Systematic active or uncontrolled infection (excluding infection of urinary tract or upper respiratory tract infection) in 14 days before the randomization\n16. Informed consent not signed or study rules violated'}, 'identificationModule': {'nctId': 'NCT02992834', 'briefTitle': 'Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma', 'organization': {'class': 'OTHER', 'fullName': "The First People's Hospital of Changzhou"}, 'officialTitle': 'Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for Chemotherapy-resistant or Refractory CD19+B Cell Lymphoma:a Double-arm, Single Center, Open-label Clinical Trial', 'orgStudyIdInfo': {'id': 'CAAA'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'IL-2 pre-treated CD19 cells', 'description': 'Initial therapy: IL-2 (interleukin,IL)stimulated, CD28-ζ-vector (cluster of differentiation 28,CD28)transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion', 'interventionNames': ['Biological: IL-2 pre-treated CD19 cells']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'IL-7/IL-15 pre-treated CD19 cells', 'description': 'Initial therapy: IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion', 'interventionNames': ['Biological: IL-7/IL-15 pre-treated CD19 cells']}], 'interventions': [{'name': 'IL-2 pre-treated CD19 cells', 'type': 'BIOLOGICAL', 'description': 'IL-2 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion', 'armGroupLabels': ['IL-2 pre-treated CD19 cells']}, {'name': 'IL-7/IL-15 pre-treated CD19 cells', 'type': 'BIOLOGICAL', 'description': 'IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion', 'armGroupLabels': ['IL-7/IL-15 pre-treated CD19 cells']}]}, 'contactsLocationsModule': {'locations': [{'zip': '213003', 'city': 'Changzhou', 'state': 'Jiangsu', 'country': 'China', 'contacts': [{'name': 'Qi Zhou, Doctor', 'role': 'CONTACT', 'email': 'dr_qzhou@163.com'}], 'facility': "First People's Hospital of Changzhou", 'geoPoint': {'lat': 31.77359, 'lon': 119.95401}}], 'centralContacts': [{'name': 'Jingting Jiang, Professor', 'role': 'CONTACT', 'email': 'jjtnew@163.com'}], 'overallOfficials': [{'name': 'Jingting Jiang, Professor', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "The First People's Hospital of Changzhou"}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'jiangjingting', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Professor', 'investigatorFullName': 'jiangjingting', 'investigatorAffiliation': "The First People's Hospital of Changzhou"}}}}